Executive Summary
There are today 83 (69) companies plus partners developing 104 (70) cytokine drugs in 205 (139) developmental projects in cancer. In addition, there are 2 (2) suspended drugs and the accumulated number of ceased drugs over the last years amount to another 6 (5) drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 20 (19) different targets. These targets are further categorized on in the software application by 6 (5) classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath. Figures in brackets are comparative data from last year.
Find and sort drugs by twelve different parameters plus free text search field. Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser, whether it is a single drug profile or an entire search you want have a report of.
How May This Drug Pipeline Update Be of Use?
* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
* Find competitors, collaborations partners, M&A candidates etc.
* Jump start competitive drug intelligence operations
* Excellent starting point for world wide benchmarking
* Compare portfolio and therapy focus with your peers
* Speed up pro-active in-/out licensing strategy work
* Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.
Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.
Drug Pipeline Update at a Glance
| Investigators | Includes more than 83 (69) principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators. Note: You are able to sort and find drugs according to investigators and partners from drop-down menus in the application. You may also sort and find drugs according to country of investigator. |
| Drug name & Synonyms | Lists commercial, generic and code names for drugs. |
| Developmental stage | This Drug Pipeline Update contains 104 (70) cytokine drugs in development, which have a total of 205 (139) developmental projects in cancer. In addition there are suspended and ceased drugs. Pipeline Breakdown According to Number of Drugs Marketed# 58 (34) Registered# 0 (1) Pre-registration# 3 (3) Phase III# 8 (2) Phase II# 15 (9) Phase I# 13 (7) Preclinical# 23 (21) No Data# 0 (2) Suspended# 2 (2) Ceased# 6 (5) Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application. |
| Indications | Included cytokine drugs are also in development for 124 (84) other indications, where of 49 (38) are different cancer indications. Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application. |
| Targets | Identified drugs are linked to more than 20 (19) different targets, divided into 6 (5) classifications of molecular function: - Cytokine activity - Metallopeptidase activity - Receptor activity - Receptor binding - Transmembrane receptor activity - Transmembrane receptor protein tyrosine kinase activity Identified targets are categorized into 5 (5) different primary and alternate sub-cellular localizations: - Cell surface - Cytoplasm - Extracellular - Golgi apparatus - Plasma membrane Note: You are able to find and sort drugs according to target gene name, molecular function of target, and target localization from drop-down menus in the application. |
| Target Expression Profile | Direct links are provided from inside the application to 20 (19) protein expression profiles of 14 (13) drug targets in various human tissues and cancer types, cell lines and primary cells, including up to: - 48 different normal tissue types - 20 different types of cancer - 47 cell lines - 12 samples of primary blood cells |
| Pathway Referals | Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG and NetPath. - BioCarta# 46 (37) Pathways - KEGG# 31 (22) Pathways - NetPath# 3 (4) Signaling Pathways Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application. |
| Mechanism | In total there are 40 (39) different drug mechanism of action represented in this Drug Pipeline Update. Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application. |
| Compound | Identified drug compounds are described by: Compound type, Chemical name, CAS Number and molecular weight Note: You are able to sort and find drugs according to compound type from drop-down menu in the application. |
| Drug Profile | Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information: Drug Name & Synonyms Presentation of drug name and synonyms Principal Investigator & Partners Presentation of principal investigator and partners Target and Molecular Function of Target Described target(s) is/are presented with: Official Gene Symbol – Official Gene Name [Species/Homo Sapiens] – Molecular Function Target Localization Described target(s) is/are presented with primary and alternate localizations. Target Expression Profiles Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to: 48 different normal tissue types 20 different types of cancer 47 cell lines 12 samples of primary blood cells Targeted Pathways Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, and NetPath. Mechanism Drug mechanism of action Developmental Projects Summary field of developmental projects for the drug, including indication, developmental stage and status. Example: Cancer, myeloma – Phase II Clinical Trial – Active Cancer, prostate – Phase III Clinical Trial – Ceased Drug Description Short introduction to drug Compound Data Compound type, Chemical name, CAS Number and molecular weight Patent Data Available patent information related to the drug is presented here. Business & Markets Collaborations and deals Approvals and submissions Analyst comments Phase III Data Available Phase III development data, developmental history and scientific data. Phase II Data Available Phase II development data, developmental history and scientific data. Phase I Data Available Phase I development data, developmental history and scientific data. Preclinical Data Available preclinical development data, developmental history and scientific data. Licensing Information Availability for licensing |
| Application Features | Use 13 different parameters, available in drop-down menus, to find and sort among drugs - Drug status - Clinical Trial Status - Principle Investigator - Partners - Indication - Developmental Stage - Compound Type - Mechanism - Target - Molecular Function of Target - Target Localization - Targeted Pathways - Free text search of entire drug profile contents Direct linkage from inside the application to related internet resources - Drug data is linked to search engines like Google and PubMed - Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, and NetPath - Direct links to company web pages of principal investigators Dynamic Report Generator Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer), whether it is a single drug profile or an entire search you want have a report of. |
| System Requirements | - Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion) - Browser Application (Internet Explorer) - Internet access (to access related internet resources) |
Other selected research from the 'Drugs' category:
Notch Signaling Pathway in Oncology Drug Pipeline Update 2011
There are today 70 companies plus partners developing 67 Notch pathway targeting drugs in 244 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 31 drugs. Notch Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 65 different targets. Learn More
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2011
There are today 203 companies plus partners developing 263 nucleic acid therapy drugs in 519 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 165 drugs. Nucleic Acid Therapies In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 173 different targets. Learn More
Other selected research from the 'Drug Pipeline Updates' category:
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2011
There are today 108 companies plus partners developing 114 IL-5 pathway targeting drugs in 373 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 46 drugs. Il-5 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 99 different targets. Learn More
Biologicals in Oncology Drug Pipeline Update 2011
There are today 675 companies plus partners developing 1185 biological drugs in 2288 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 642 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 407 different targets. Learn More
Other selected research from the 'Oncology' category:
Triple Analysis: Colorectal Cancer, Melanoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Melanoma and Pancreatic Cancer. Learn More
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
This report comprises defined and up to date development strategies for 239 angiogenesis affecting drugs in oncology within the portfolio of 148 corporate investigators, from Ceased to Marketed. The report extensively analyses their 174 identified drug targets, organized into 167 drug target strategies, and assesses them in 64 different cancer indications. Learn More
Other selected research from the 'Immunomodulators' category:
Antibodies in Oncology Drug Pipeline Update 2011
There are today 294 (248) companies plus partners developing 613 (472) antibody drugs in 1241 (947) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 291 (285) drugs. Antibodies In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 260 (229) different targets. Learn More
Cancer Vaccines Drug Pipeline Update 2011
There are today 216 (195) companies plus partners developing 278 (209) cancer vaccine drugs in 500 (343) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 168 (173) drugs. Cancer Vaccines Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 110 (97) different targets. Learn More